Alzheimer'S Disease Clinical Trials in Chicago, IL

View the best 10 alzheimer's disease medical studies in Chicago, Illinois. Access promising new therapies by applying to a Chicago-based Alzheimer'S Disease clinical trial.

Trials in Chicago, Illinois

Here are the top 10 medical studies for alzheimer's disease in Chicago, Illinois

Michael Bask Gill, B Sc

Last Reviewed: December 24th, 2024

Patient-Centered Dementia Care Practice Coaching Intervention

Behavioral Intervention

Recruiting1 award

"This trial aims to see if staff in long-term care communities benefit from a specific intervention. They want to know if the intervention affects employee satisfaction and confidence in dementia care. The intervention group will receive coaching

Negotiation Training

Behavioral Intervention

Recruiting1 award7 criteria

This trial aims to improve communication between family caregivers and those with cognitive impairment & Alzheimer's Disease.

Donanemab

Monoclonal Antibodies

Verified

Recruiting1 awardPhase 3

This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.

PERSEVERE

Behavioural Intervention

Recruiting1 award

"This trial aims to study the impact of an intervention called PERSEVERE on family caregivers of individuals with Lewy Body Dementia. The study will focus on how PERSEVERE can improve caregiver

ABBV-916

Verified

Recruiting0 awardsPhase 2

This trial is testing a new drug called ABBV-916 to see if it can help people aged 50-90 who are in the early stages of Alzheimer's disease. Participants will receive the drug regularly over several months. The study aims to find out if the drug is safe and effective by monitoring changes in symptoms and side effects.

AVP-786

Behavioural Intervention

Verified

Recruiting1 awardPhase 3

This trial tests a combination of two drugs taken by mouth to help calm severe agitation in people with Alzheimer's disease by balancing brain chemicals.

KarXT

Behavioural Intervention

Verified

Recruiting2 awardsPhase 3

This trial will assess the long-term safety and tolerability of KarXT for people with Alzheimer's-related psychosis.

Communication Strategies Information/Counseling +1 More

Behavioral Intervention

Recruiting1 award3 criteria

This trial aims to see if Over-the-Counter (OTC) hearing aids can help improve communication in patients with mild to moderate hearing loss and mild cognitive impairment or Alzheimer's disease. The study will

MyCog

Recruiting1 award3 criteria

This trial aims to provide real-world evidence on a sustainable method to identify and manage cognitive impairment and dementias in primary care settings. The study will test a new approach derived from the NIH Toolbox to

Gantenerumab

Monoclonal Antibodies

Recruiting0 awardsPhase 2 & 3

This trial will study if treatment with an investigational study drug can prevent or slow the rate of Alzheimer's disease (AD)-causing accumulation of amyloid beta (Aβ). Part 1 will use Aβ positron emission tomography (PET) imaging to determine if treatment with the study drug prevents or slows the rate of Aβ pathological disease accumulation. Part 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD.

Popular Filters

Phase 3 Trials

Monoclonal Antibodies

Investigational Alzheimer's Drugs for Early Onset Alzheimer's Disease

Recruiting0 awardsPhase 2 & 3

Park Ridge, Illinois

This trial tests two drugs, lecanemab and E2814, in people with a genetic mutation that causes Alzheimer's disease. Lecanemab helps remove harmful protein clumps from the brain, while E2814 prevents harmful protein tangles from forming. The goal is to see if these drugs can slow down or improve symptoms of Alzheimer's.

Piromelatine for Alzheimer's Disease

Recruiting0 awardsPhase 2 & 3

Milwaukee, Wisconsin

This trial tests piromelatine, a pill taken before bed, in people with mild Alzheimer's who lack a specific genetic variation. The goal is to see if it can improve brain function and slow down dementia progression.

Monoclonal Antibodies

Donanemab for Alzheimer's Disease

Recruiting1 awardPhase 3

Chicago, Illinois

This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.

Glucagon-like peptide-1 (GLP-1) receptor agonist

Semaglutide for Early Alzheimer's Disease

Recruiting1 awardPhase 3

Paw Paw, Michigan

This trial is to test whether the medication semaglutide has a positive effect on early Alzheimer's disease. The study will last for up to 173 weeks, and participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans, and at 10 of the clinic visits participants will have blood samples taken. The trial is only for women.

Glucagon-like peptide-1 (GLP-1) receptor agonist

Semaglutide for Early Alzheimer's Disease

Recruiting1 awardPhase 3

Paw Paw, Michigan

This trial is testing whether semaglutide has a positive effect on early Alzheimer's disease by comparing it to a placebo. There will be 17 clinic visits and 1 phone call with the study doctor, and various tests and scans will be performed. The study will last for up to 173 weeks.

Behavioural Intervention

AVP-786 for Alzheimer's-related Agitation

Recruiting1 awardPhase 3

Chicago, Illinois

This trial tests a combination of two drugs taken by mouth to help calm severe agitation in people with Alzheimer's disease by balancing brain chemicals.

Trials With No Placebo

Behavioral Intervention

Communication Training for Alzheimer's Caregivers

Recruiting1 award7 criteria

Chicago, Illinois

This trial aims to improve communication between family caregivers and those with cognitive impairment & Alzheimer's Disease.

Behavioural Intervention

KarXT for Alzheimer's-Related Psychosis

Recruiting2 awardsPhase 3

Berwyn, Illinois

This trial will assess the long-term safety and tolerability of KarXT for people with Alzheimer's-related psychosis.

MyCog for Cognitive Impairment

Recruiting1 award3 criteria

Chicago, Illinois

This trial aims to provide real-world evidence on a sustainable method to identify and manage cognitive impairment and dementias in primary care settings. The study will test a new approach derived from the NIH Toolbox to

Small Molecule

Long-Term Safety of Simufilam for Alzheimer's Disease

Recruiting2 awardsPhase 3

Dayton, Ohio

This trial looks at how safe a drug is over time for people who have already taken it in a previous trial.

Behavioral Intervention

Improvised Music for Alzheimer's Disease

Recruiting1 award

Chicago, Illinois

This trial aims to study the effects of a type of calming improvised music called Clinically Designed Improvisatory Music (CDIM) on reducing anxiety in both healthy individuals and Alzheimer's patients with anxiety.

Behavioural Intervention

PAINAD Scale for Painful Dementia

Recruiting1 award

Chicago, Illinois

"This trial aims to see if using the Pain in Advanced Dementia (PAINAD) scale can help emergency department staff provide better pain care for people with dementia. They believe that by using an electronic

View more alzheimer's-disease clinical trials chicago

See more medical studies focusing on alzheimer's-disease chicago

Frequently Asked Questions

Do I need insurance to participate in a trial?

Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).

Is there any support for travel costs?

Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.

Will I know what medication I am taking?

This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.

How long do clinical trials last?

Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.

Do you verify all the trials on your website?

All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.

How quickly will I hear back from a clinical trial?

Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.